Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (Nasdaq: IMNM) announced that on December 1, 2025 its Compensation Committee granted inducement non‑statutory stock options to four new employees totaling 88,000 shares under the Company’s 2024 Inducement Plan.
Each option has an exercise price of $18.32 per share (the company’s closing price on December 1, 2025) and vests over four years: 25% at the one‑year anniversary and the remainder monthly over the following 36 months, subject to continued service and the plan and option agreement terms.
Immunome (Nasdaq: IMNM) said members of management will present at two investor conferences on December 3, 2025. Presentations and times: Piper Sandler 37th Annual Healthcare Conference at 9:00 a.m. ET and Evercore 8th Annual Healthcare Conference at 9:10 a.m. ET. Interested parties can listen via live audio webcasts on the company’s Investor Relations website at www.immunome.com. Replay webcasts will be available for approximately 30 days after each live presentation.
Immunome (Nasdaq: IMNM) reported third quarter 2025 results and a program update on November 6, 2025. Cash and cash equivalents were $272.6 million as of September 30, 2025, including $44.9 million net proceeds from its at-the-market equity offering; the company expects this cash to fund operations into 2027.
Clinical highlights: topline data for the Phase 3 RINGSIDE Part B study of varegacestat is expected before end of 2025; objective responses were observed at multiple dose levels in B-cell lymphoma patients treated with IM-1021, with initial IM-1021 data planned for 2026. IND clearance for IM-3050 was received in April 2025.
Quarterly expenses included R&D of $49.2 million and G&A of $10.9 million; net loss was $57.5 million.
Immunome (Nasdaq: IMNM) announced that on Nov. 3, 2025 its Compensation Committee granted inducement stock options to three new employees under the company’s 2024 Inducement Plan.
The grants total 19,000 nonstatutory stock options with an exercise price of $17.00 per share (the company’s closing price on Nov. 3, 2025). The options vest over four years: 25% at the one-year anniversary of the vesting commencement date and the remainder vesting monthly over the following 36 months, subject to continued service, and are governed by the 2024 Inducement Plan and individual option agreements.
The Compensation Committee approved the awards as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ: IMNM) said management will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on Tuesday, Nov. 11, 2025 at 8:30 a.m. ET.
Investors can listen via a live audio webcast from the company Investor Relations website at www.immunome.com. A replay will be available for approximately 30 days after the live presentation.
Immunome (Nasdaq: IMNM) presented preclinical data on Oct. 23, 2025 showing its proprietary ADC payload HC74 overcomes several ADC resistance mechanisms, including payload efflux and target heterogeneity.
The poster reported HC74 is a novel topoisomerase I inhibitor used in IM-1021 (a ROR1-targeted ADC in Phase 1) and in multiple preclinical candidates; key findings include high membrane permeability, robust bystander activity, and efficacy in preclinical models refractory or resistant to trastuzumab-DXd, irinotecan, and models with heterogeneous target expression.
A copy of the poster is available in the company’s Events & Presentations materials.
Immunome (Nasdaq: IMNM) announced that on Oct. 1, 2025 its Compensation Committee granted inducement awards of 69,000 non‑statutory stock options to purchase common stock to five new employees under the 2024 Inducement Plan.
Each option has an exercise price of $11.34 equal to the Company’s closing price on Oct. 1, 2025, and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and the terms of the 2024 Inducement Plan and the applicable stock option agreements. The grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ:IMNM) has entered into a research collaboration agreement with Infinimmune for novel antibody discovery and optimization. The partnership leverages Infinimmune's GLIMPSE™ and Anthrobody® platforms to transform early-stage antibodies into development-ready therapeutic candidates.
Under the agreement, Immunome receives target exclusivity, with Infinimmune handling antibody discovery and optimization while Immunome will manage development and commercialization of resulting candidates. Financial terms were not disclosed.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced inducement grants to new employees. The Compensation Committee approved non-statutory stock options for 117,000 shares of common stock to 8 new employees under the company's 2024 Inducement Plan.
The stock options have an exercise price of $9.28 per share, based on the company's closing price on September 2, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Immunome (NASDAQ:IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's management will deliver a presentation on Tuesday, September 9, 2025, at 1:00 p.m. Eastern Time.
Investors and interested parties can access the presentation through a live audio webcast available on the Investor Relations section of Immunome's website. The presentation recording will remain accessible for approximately 30 days following the live event.